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E-mail address: korn@lrz.tum.de (T. Korn).Although experimental autoimmune encephalomyelitis (EAE) is limited in its potency to reproduce
the entirety of clinical and histopathologic features of multiple sclerosis (MS), this model has been
successfully used to prove that MS like autoimmunity in the CNS is orchestrated by autoantigen spe-
ciﬁc T cells. EAE was also very useful to refute the idea that IFN-c producing T helper type 1 (Th1)
cells were the sole players within the pathogenic T cell response. Rather, ‘‘new’’ T cell lineages such
as IL-17 producing Th17 cells or IL-9 producing Th9 cells have been ﬁrst discovered in the context of
EAE. Here, we will summarize new concepts of early and late T cell plasticity and the cytokine net-
work that shapes T helper cell responses and lesion development in CNS speciﬁc autoimmunity.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Multiple sclerosis (MS) is the most common inﬂammatory
demyelinating disease in adult humans. Although its prevalence
is only about 1 in 1000 in Europe and the US, MS imposes a heavy
medical and economic burden on the society since it affects young
individuals in the most productive years of their lives [1]. The clin-
ical course of MS is relapsing remitting (RRMS) in about 70–80% of
patients. However, after a disease duration of 10 years, almost half
of the affected individuals experience a deterioration of symptoms
independently of relapses and enter into the secondary progressive
phase of the disease [2]. Many hypotheses have been put forward
on the etiology of MS and all of them have been disproved except
for one: the autoimmune hypothesis that argues in favor of the
idea that the myelin sheath is attacked by autoantigen speciﬁc im-
mune cells [3–6]. First, all the gene polymorphisms that have been
validated in genome wide association studies to be associated with
increased risk of developing MS affect immune genes. Prominent
examples are HLA class II DRB1⁄1501, IL2R, IL7R, CD58, and
IL12p35 [7]. None of these genes has a role in the development
or homeostasis of oligodendrocytes, astrocytes, or neurons. Second,
animal models of primary oligodendropathies do not recapitulate
histopathological hallmark features of MS [8–11]. Third (and per-
haps most importantly), therapeutic strategies that have been de-
rived from the animal model of inﬂammatory demyelination, i.e.,al Societies. Published by Elsevierexperimental autoimmune encephalomyelitis (EAE) are at least
partially efﬁcient in MS patients [12–15].
The current concept of the pathologic cascade in MS has largely
been developed in EAE and the most important key feature of this
concept is that immunological tolerance of autoreactive T cells is
broken [16–18]. Breach of tolerance can be due to a multitude of
reasons including elevated frequencies of autoreactive T cells,
molecular mimicry of foreign antigens that activate T cells that
have degenerate T cell receptors (TcR), true cross reactivity of T
cells that express two different TcRs, one of which recognizes a for-
eign antigen while the other one is autoreactive, or failure of reg-
ulatory T cells. Once autoreactive T cells are triggered in the
peripheral immune compartment, a chain of events is started.
Every step in this sequence of events, i.e. crossing of the blood
brain barrier, re-activation in the perivascular compartment, inﬁl-
tration into the CNS parenchyma, immune cell/target cell interac-
tion within the CNS parenchyma, lesion development, and
resolution of inﬂammation as well as tissue repair have all been
extensively studied in EAE [18,19]. During the last 30 years, EAE
has become one of the most successful animal models in preclini-
cal research and basic T cell immunology. Indeed, EAE in its multi-
ple variants does not only recapitulate histopathological features
of MS as a prototypic organ speciﬁc autoimmune disease but is also
a suitable model to study T cell development during immune reac-
tions in vivo. Here, we will focus on the development of various
species of effector T cells and the cytokine network involved in
their generation as well as the effector cytokines that eventually
induce immunopathology during autoimmune CNS inﬂammation.B.V. Open access under CC BY-NC-ND license.
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Upon recognition of their cognate antigen in the context of MHC
class II molecules and in the presence of co-stimulatory signals as
well as cytokine cues provided by innate immune cells, CD4+ T cells
are activated and initiate a developmental program that leads to
the commitment of the T cell to a speciﬁc effector cell phenotype.
It has long been recognized that there are at least two distinct
effector T helper cell phenotypes that are deﬁned by a characteris-
tic cytokine signature. This categorization into IL-4 producing Th2
and IFN-c producing Th1 cells was ﬁrst introduced by Mosmann
et al. who were looking for CD4+ T cell subsets that were particu-
larly suited to give B cell help and found that IL-4 producers but
not IFN-c producers were very efﬁcient in promoting the produc-
tion of IgG1 in murine B cells [20]. Besides IL-4, Th2 also secrete
IL-5 and IL-13 but no IFN-c. In contrast Th1 cells produce IFN-c,
TNF, and lymphotoxin, but no IL-4. Th1 cells activate macrophages
and thus mediate phagocyte-dependent protective immune
responses.
The generation of Th1 cells from a naïve CD4+ T cell precursor
requires IL-12, a cytokine that is strictly T cell-extrinsic and is pro-
duced by activated antigen-presenting cells (APCs) [21]. Upon
sensing small amounts of IFN-c derived from innate immune cells
in combination with TcR signaling, the transcription factor T-bet is
upregulated in a Stat1 (signal transducer and activator of transcrip-
tion 1) dependent manner. T-bet, in turn, induces the expression of
IL-12Rb2 rendering nascent Th1 cells responsive to IL-12. IL-12, via
Stat4, further transactivates T-bet, which is the most important
transcription factor to stabilize the production of large amounts
of IFN-c determining the terminal commitment of T cells to the
Th1 lineage [22]. Because T-bet and Gata3, the master transcription
factors for Th1 and Th2 cells, respectively [23,24], cross-inhibit
each other [25], it has long been thought that the commitment of
T cells to the Th1 vs Th2 lineages was mutually exclusive, but this
view has recently been changing (see below).
Since the histopathological and clinical features not only in EAE
and MS but also in other organ-speciﬁc autoimmune diseases like
rheumatoid arthritis or psoriasis, could be explained by Th1 effec-
tor mechanisms, these cells and their key cytokine IFN-c were
thought to be the major mediators of organ-speciﬁc autoimmunity.
IFN-c was identiﬁed in the lesions of MS patients and administra-
tion of recombinant IFN-c triggered MS-relapses [26,27]. The fact
that myelin antigen speciﬁc T cell lines that had a pure Th1 pheno-
type were very potent in inducing EAE upon adoptive transfer into
recipient animals was also a very strong argument in favor of EAE
(and putatively also MS) as being a ‘‘Th1’’ disease. Consistent with
this idea, Tbx21/ (T-bet deﬁcient) mice were resistant to MOG35–55
induced EAE and neutralizing antibodies to the p40 subunit of IL-
12 reduced the disease severity in EAE mice [28,29]. However, as
of the mid 1990s it was difﬁcult to reconcile the Th1 concept of
EAE with the observation that the newly generated Ifng/ mice
and Ifngr/ mice as well as Il12p35/ mice were not resistant to
EAE, but were even hypersusceptible to the disease [30–32]. It
was later discovered that the p40 subunit of IL-12 not only paired
with p35 to form the biologically active heterodimeric molecule of
IL-12, but also with a p19 subunit to form a cytokine that was
termed IL-23 [33]. IL-23 did not induce Th1 cells but promoted
the secretion of a phylogenetically ancient cytokine, IL-17, in
CD4+ T cells. IL-17 had been cloned in 1993 [34,35]but did not re-
ceive a lot of attention because it had not been associated with
adaptive T helper cell responses up to then. Il23p19/mice (which
do not produce IL-23, but whose production of IL-12 is not im-
paired) were completely resistant to any model of induced autoim-
munity including EAE [36]. Thus, as of 2003 the IL-23/IL-17 axis
rapidly moved into the focus of research interest in autoimmunityand chronic inﬂammation. Since IL-17 cannot be classiﬁed accord-
ing to the Th1/Th2 paradigm, IL-17 producing CD4+ T helper cells
were termed Th17 cells. However, whether or not Th17 cells are
a T helper cell lineage of their own, kindled a serious debate among
T cell immunologists. Even though the minimal requirements for
the deﬁnition of a ‘‘new’’ lineage, i.e. identiﬁcation of the differen-
tiation factors that induce Th17 cells from naïve T cells, character-
ization of a distinct cytokine signature that is linked to distinct
effector functions of Th17 cells, and identiﬁcation of a ‘‘master’’
transcription factor that controls the transcription of the signature
cytokines of Th17 cells have all been met [37–39], it remains a con-
cern that Th17 cells, in contrast to Th1 cells, do not seem to be sta-
ble in vivo and it is still not entirely clear whether long lived
memory T cells can be generated from the Th17 lineage [40]. Yet,
Th17 cells are found in the inﬂamed CNS of EAE mice and IL-17
is one of the cytokines that is strongly upregulated in MS lesions
[41], in the skin of psoriasis patients [42], in the gut of patients
with chronic inﬂammatory bowel disease [43], and in the joints
of patients with rheumatoid arthritis [44].
Further T helper cell subsets such as Th9 cells or Th22 cells have
recently been described based on their signature cytokines IL-9
and IL-22, respectively [45–48]. However, for these Th subsets it
is even less clear than for Th17 cells whether they represent stable
lineages. Th9 cells are induced by TGF-b plus IL-4 and produce
exceptionally large quantities of IL-9, high levels of IL-10 but only
trace amounts of IL-17 or IFN-c. Since IL-9 was formerly thought to
be a Th2 speciﬁc cytokine, most of the effector functions of Th9
cells were observed in models of allergic diseases. Indeed Th9 cells
act as key players in onset and progression of asthma serving as
strong inducers of mast cell responses [47]. However, despite ma-
jor differences in differentiation modes and functions, Th1, Th17
and Th9 cells are able to contribute to the pathogenesis of EAE
and MS [49]. Each T helper cell subset produces speciﬁc cytokines
which act as critical components of the immune inﬂammatory pro-
cess and are the key means by which T helper cells amplify im-
mune responses and recruit other effector cells of the adaptive
and innate immune system to shape speciﬁc types of immunity
(Fig. 1). In order to understand the coordinate recruitment of var-
ious effector cell subsets to the site of inﬂammation, it has been an
important focus in EAE research to elucidate the temporal and spa-
tial pattern of cytokine expression in the CNS during an autoim-
mune response (see also Table 1).
3. IFN-c
IFN-c, the hallmark Th1 cytokine, plays a signiﬁcant role both in
immunostimulation and immunomodulation. IFN-c was ﬁrst de-
scribed by Wheelock as an interferon-like virus inhibitor produced
by human leukocytes [50]. IFN-c, the only member of the type II
class of interferons, has been cloned and is located on human chro-
mosome 12 [51] and mouse chromosome 10 [52]. The Ifng gene is
highly conserved among species and contains four exons and three
introns [53]. The biologically active IFN-c protein is built from two
monomers in an anti-parallel inter-locking manner.
IFN-c is produced by NK and NKT cells that belong to the innate
immune system but is also a major product of activated T cells (see
above). The IFN-c receptor is composed of two subunits: the
ligand-binding a-chain [54] and the transmembrane b-chain, that
is essential for intracellular signaling [55,56]. Whereas the a-chain
is ubiquitously and constitutively expressed, the expression of the
b-chain is induced by distinct stimuli [57]. Upon binding of IFN-c
to its receptor the receptor associated Janus kinases Jak1 and
Jak2 become phosphorylated and phosphorylate in turn the down-
stream transcription factor Stat1a which binds to speciﬁc DNA
elements (IFN-c-activation sites) [58]resulting in rapid direct or
Fig. 1. Model of T helper cell differentiation. Naïve T cells can differentiate into T
helper type 1 (Th1), Th2, Th17 or Th9 cells depending on the cytokine environment.
The transcription factors Gata3, T-bet, Ror-ct or PU.1, and Irf4 are among others
required for the induction of Th2, Th1, Th17, or Th9 cells, respectively. Each T helper
cell subset secrets a distinct panel of effector cytokines, which in turn, affects
distinct types of target cells.
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Fcc receptor or MHC class I and II [59].
IFN-c has a great impact on the regulation of the immune re-
sponse [60] since many immune cells express the IFN-c receptor
and respond to IFN-c: IFN-c stimulates the differentiation of Th1
cells, inhibits the differentiation of Th2 cells [61] and activates
cytotoxic T cells and NK cells [62]. Furthermore IFN-c inﬂuences
antibody production by promoting the secretion of IgG2a by B cells
[63] and stimulates macrophages to produce tumor necrosis factor
(TNF), IL-1, IL-6 and IL-8 [64]. Because of its inﬂuence on Th1 cellsTable 1
Effector cytokines in EAE.
Cytokine Source Receptor/
IFN-c T cells, NKT cells, NK cells Heterodim
IL-17A Th17 cells, CD8+ T cells, cd T cells, NKT cells, NK cells,
LTi cells, LTi-like cells, neutrophils, eosinophils, monocytes
Functiona
IL-17RA:
endotheli
IL-17RC:
cells, low
IL-21 Th17 cells, T follicular helper cells, NKT cells, NK cells Functiona
cc: on lym
non-hem
IL-21R: o
myeloid c
IL-9 Th9 cells, Th2 cells, Treg cells, NKT cells, mast cells Functiona
cc: on lym
non-haem
IL-9Ra: T
cells, airw
IL-22 Th17 cells, activated T cells, cd T cells, NKT cells, NK cells, LTi
cells, LTi-like cells
Functiona
IL-10R2:
non-hem
IL-22R1:
tissues, b
TNF Activated T cells, B cells, NK cells, monocytes, macrophages
(main producers), dendritic cells, astrocytes, microglia
TNFR1 (p
T cells or
TNFR2 (p
oligodend
GM-CSF Activated T cells, macrophages, dendritic cells (CD103+),
endothelial cells, ﬁbroblasts, mesothelial cells
Functiona
On neutro
macrophaand macrophages, IFN-c was thought to be crucial for the induc-
tion of EAE. Indeed, in mice, high levels of IFN-c could be detected
in the CNS at the peak of EAE disease, but declined during recovery
[65]. However, unexpectedly, mice deﬁcient for IFN-c or IFN-c
receptor were fully susceptible to EAE and even experienced an
EAE with higher morbidity and mortality [30,31]. Although it is
now known that IFN-c is also pro-apoptotic and initiates the con-
traction of effector T cell populations [66,67], development of EAE
in the genetic absence of IFN-c eliminated this cytokine as unique
non-redundant pathogenic factor in T cell mediated organ-speciﬁc
autoimmunity.
4. IL-17
IL-17 (IL-17A) is the prototypic cytokine of the IL-17 family
which contains IL-17, IL-17B, IL-17C, IL-17D, IL-17E (also called
IL-25), and IL-17F, which share 16–50% amino acid identity
[68,69]. Members of the IL-17 family of cytokines are structurally
homologous to the cysteine knot family of proteins. IL-17A and
IL-17F are the best characterized family members and have distinct
but overlapping (mostly proinﬂammatory) functions. IL-17F is
more important in mucosa associated immune responses [70]. IL-
17A and IL-17F are secreted by several cell types including subsets
of CD4+ T cells, CD8+ T cells, cd T cells, NKT cells, NK cells and neu-
trophils. In contrast, IL-17E (also called IL-25) is associated with
Th2 responses and is secreted by Th2 cells, mast cells, but also
intestinal epithelial cells. The receptor complex for IL-17E consists
of a IL-17RA/IL-17RB heterodimer and thus, shares the IL-17RA
subunit with the receptor for the proinﬂammatory family mem-
bers IL-17A and IL-17F, which is a heterodimeric molecule com-
posed of IL-17RA and IL-17RC. Sharing of IL-17RA by IL-17A,
IL-17F, and IL-17E might be one of the reasons why the clinical
phenotype of Il17ra/mice that are not resistant to EAE, has been
difﬁcult to interpret. In fact, IL-17A (more than IL-17F) plays a
disease promoting role in EAE while IL-25 is protective [70,71].
Through IL-17RA binding, IL-17A activates NFjB signaling and
MAP kinases. Because IL-17A treatment failed to induce NFjB asreceptor distribution Refs.
er: IFN-cRa/b: inducible on all nucleated cells [180–183]
l heterodimer: IL-17RA/C
on hematopoietic cells, osteoblasts, ﬁbroblasts,
al cells, epithelial cells
on epithelial cells, ﬁbroblasts and other stromal
amounts on hematopoietic cells
[34,36,147,148,159,184–191]
l heterodimer: cc/IL-21R
phoid, but not on non-lymphoid and
atopoietic cells
n B cells, T cells, NK cells, some populations of
ells
[87–89,192–195]
l heterodimer: cc/IL-9Ra
phoid, but not on non-lymphoid and
atopoietic cells
cells, B cells, mast cells, macrophages, dendritic
ay epithelial cells, immature neurons
[45,46,90,96,196–203]
l heterodimer: IL-10R2/IL-22R1
ubiquitously expressed on hematopoietic and
atopoietic cells
on a variety of epithelial and parenchymal
ut not on lymphoid cells
[108,118,120,204–209]
55): on all nucleated cells (not on unstimulated
unstimulated oligodendrocytes)
75): expression on hematopoietic cells and
rocytes
[62,124,210–215]
l heterodimer: bc/GM-CSF(CSF2)Ra
phils, eosinophils, basophils, monocytes,
ges, dendritic cells, microglia, endothelial cells
[139,145,146,216–223]
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ubiquitin ligase TRAF6, TRAF6 has been suggested to be involved
in the IL-17A induced NFjB activation [72]. TRAF6 is recruited to
the IL-17RA chain by the adaptor protein Act1, which binds di-
rectly to the SEFIR domain of IL-17RA [73]. Thus, Act1 and TRAF6
mediate downstream signaling of IL-17RA [74,75]. IL-17A induces
several proinﬂammatory cytokines (IL-6, IL-1b, TNF, GM-CSF) and
chemokines, in particular CCL20, which can attract CCR6 express-
ing Th17 cells in a positive feed forward loop, and ELR+ (glutamic
acid (E), leucin (L), arginine (R)) members of the CXC family of
chemokines (CXCL1 and CXCL2) that are strong attractants for
neutrophils [76,77]. Moreover IL-17R engagement increases the
generation of reactive oxygen species (ROS) in brain endothelial
cells resulting in disorganization of tight junctions and subse-
quently in blood brain barrier impairment [78,79]. Furthermore
IL-17A is thought to activate microglial cells [80]. Since upon stim-
ulation with IL-17, innate immune cells produce IL-1b and IL-6
which are factors that promote the differentiation of adaptive
immune cells towards the Th17 phenotype, this cytokine network
might constitute a feed forward loop resulting in enhanced tissue
inﬂammation [81].5. IL-21
IL-21 is a member of the IL-2 family of cytokines. IL-21 plays a
signiﬁcant role in the activation of NK cells and promotes the
expansion of B cells and T cells that have been activated by their
cognate antigen [82]. It is produced by NKT cells, but also by acti-
vated CD4+ T cells, especially by Th17 cells and follicular T helper
cells. The functional IL-21 receptor is a heterodimer composed of
the common c-chain (cc) which is shared by the receptors for IL-
2, IL-4, IL-7, IL-9, and IL-15, and the unique IL-21 receptor a chain
(IL-21Ra) [83]. Upon receptor binding, IL-21 activates both Jak1
and Jak3 resulting in signal transduction via Stat3 and Stat1 and
to a weaker extent via Stat5.
IL-21 is a T cell derived cytokine that has a prominent role in the
communication of T cells with other immune cells. IL-21 is in-
volved in the regulation of immunoglobulin production and termi-
nal differentiation of B cells into plasma cells [84,85]. IL-21 induces
the expression of killer inhibitory receptors (KIRs) on NK cells and
thus augments their cytolytic activity. A combination of IL-15 and
IL-21 increases the production of IFN-c by NK cells [86]. Among
effector T helper cells, the largest quantities of IL-21 are produced
by Th17 cells. And similar to IL-4 for Th2 cells and IFN-c for Th1
cells, IL-21 serves as an autocrine ampliﬁer molecule for the gener-
ation of Th17 cells since IL-21 together with TGF-b is able to drive
the generation of Th17 cells from naïve T cells [87–89]. Thus, IL-21
acts back on T cells to increase the Th17 precursor frequency and
also on other immune cells to promote speciﬁc effector functions.
Due to the restricted expression of the functional IL-21 receptor,
which is not expressed on non-hematopoietic cells, IL-21 – unlike
IL-17 – does not induce a broad tissue response.6. IL-9
Like IL-21, IL-9 is a member of the common c-chain receptor
cytokine family. Cellular sources of IL-9 are mast cells but also T
cells. IL-9 has been thought to be part of the Treg signature but
more recently it has been conﬁrmed that IL-9 may be produced
by a speciﬁc subset of T helper cells (Th9 cells) that can be induced
in vitro with a combination of TGF-b and IL-4 [45,46,90]. Minor
amounts of IL-9 may also be produced by Th2 and Th17 cells. IL-
9 activates a heterodimeric receptor consisting of the cytokine-
speciﬁc IL-9 receptor a chain (IL-9Ra) and the common c-chain
[91]. Upon binding of IL-9 to its receptor, the kinases Jak1 andJak3 are phosphorylated and subsequently activate Stat1, Stat3
and Stat5 [92–94].
IL-9 was initially described as a cytokine that promotes the
expansion of mast cells [95]. Il9/mice harbor normal steady state
concentrations of mast cells, but show defects in the expansion and
recruitment of mast cell populations after intestinal nematode
infections or EAE induction [96,97]. The proinﬂammatory charac-
teristics of IL-9 are further supported by the observation that anti-
gen-speciﬁc, adoptively transferred Th9 cells are able to induce
EAE [49]. However, the net effect of IL-9 depends on the cellular
context. There are hints that IL-9 may act directly on Tregs (which
express IL-9Ra), enhancing their suppressive function and indi-
rectly on Th17 cells (which do not express IL-9Ra), promoting their
proliferation and/or accumulation [98]. IL-9 induces the expression
of the chemokine CCL20 by astrocytes, which enhances the migra-
tion of Th17 cells into the CNS. Accordingly mice treated with a
neutralizing anti-IL-9 antibody showed reduced expression of
CCL20 in astrocytes and decreased numbers of inﬁltrating Th17
cells resulting in reduced EAE [99].7. IL-22
IL-22, which is part of the Th17 cytokine signature, is induced
upon IL-23R engagement and is also produced by NK cells, NKT
cells, cd T cells and lymphoid tissue inducer (LTi) cells. IL-22 is a
member of the IL-10 family of cytokines, which also includes IL-
10, IL-19,IL-20, IL-24, IL-28a, and IL-28b as well as IL-26 and IL-
29, two IL-10 family members that are only expressed in humans
[100–103]. Whereas the Il29 gene exists in mice, but is non-
functional due to the existence of a stop codon within the ﬁrst exon
[104,105], the Il26 gene is disrupted in rodents [106]. The unique
IL-22R is a heterodimeric transmembrane receptor complex con-
sisting of IL-22R1 and IL-10R2. Binding of IL-22 to its receptor acti-
vates Jak-Stat signaling pathways, in particular Stat3. In addition to
the cell surface receptor complex, there is a secreted IL-22 binding
receptor, termed IL-22 binding protein (IL-22BP), which is encoded
by an independent gene that lacks sequences for the intracellular
and transmembrane domains of IL-22R [107–110]. In vitro, IL-
22BP binds IL-22 and inhibits the binding of IL-22 to its cell mem-
brane associated receptor. Interestingly, IL-22BP expression is
downregulated under inﬂammatory conditions [111,112]. This
suggests that IL-22 is the only IL-10 family member whose func-
tional activity can be regulated even after its secretion.
Similar to IL-17, IL-22 has a broad impact on epithelial cells.
However, in contrast to IL-17RA and IL-17RC, the functional IL-22
receptor complex is not expressed on hematopoietic cells. Thus,
IL-22 modulates local tissue responses and targets cells of the skin,
the digestive tract, the lungs and the kidney and promotes cell pro-
liferation and differentiation, thereby enhancing host defence and
wound-healing responses [113]. Moreover IL-22 exhibits protec-
tive functions by limiting tissue damage during inﬂammatory pro-
cesses of the liver [114], the gut [115,116]and the myocardium
[117]. The role of IL-22 in autoimmunity is not yet clear. Whereas
IL-22 exacerbates the inﬂammatory skin response in psoriasis
[118–120], the effector functions of IL-22 in EAE are not well
understood. While IL-22 contributes to breaching of the blood
brain barrier [78], IL-22 KO mice do not show a reduced phenotype
in the EAE model [121].8. TNF
TNF is mainly produced by activated mononuclear phagocytic
cells, but also by NK cells, B cells, activated T cells, as well as by
resident cells of the CNS including astrocytes and microglial cells.
TNF is generated as a 27 kDa membrane-bound protein. Upon
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ing enzyme (TACE), the resulting 17 kDa fragments form homo-
trimers and thus build the soluble active form of the cytokine. Both
the transmembrane and the soluble forms are biologically active.
There are two types of TNF receptors: TNF receptor 1 (TNFR1,
p55) is broadly expressed and can be activated by either soluble
or transmembrane TNF. TNF receptor 2 (TNFR2, p75) is preferen-
tially activated by the transmembrane form of TNF [122,123] and
is expressed by cells of the immune system including microglia
but also by macroglial cells. Oligodendrocytes express TNFR2 in a
constitutive manner and are induced to express TNFR1 by inﬂam-
matory stimuli [124]. While TNFR1 confers cytotoxic effects and
promotes apoptosis, TNFR2 mediated signaling modulates apopto-
sis but can also result in cell growth and proliferation [125].
More than 15 years ago, TNF was identiﬁed in active MS brain
lesions, both on the protein and mRNA level [126,127]. Thus, TNF
was considered to be involved in Th1 mediated tissue damage.
Accordingly, elimination of TNF producing macrophages, applica-
tion of a neutralizing anti-TNF antibody or of a soluble p55 mole-
cule prevented the induction of EAE [128–130] whereas
administration of recombinant TNF exacerbated clinical symp-
toms. [131]. Similarly, transgenic mice overexpressing TNF in the
CNS developed a spontaneous inﬂammatory demyelinating disease
and this demyelination was completely reversed by a neutralizing
anti-TNF antibody [132]. In line with these ﬁndings, Tnfr1(p55)/
mice were totally resistant to EAE. However, Tnfr2(p75)/ mice
exhibited exacerbated EAE, with increased Th1 cytokine produc-
tion, and increased inﬁltration of CD4+ T cells and macrophages
in the CNS [133]. Also, mice deﬁcient for TNF were not protected
from EAE; they even developed a more severe variant of EAE, char-
acterized by extensive inﬂammation and demyelination [134].In-
deed, after toxic demyelination, Tnfr2(p75)/ mice showed
reduced proliferation of oligodendrocyte precursor cells and thus,
impaired remyelination as compared with wild type littermates
or Tnfr1(p55)/mice suggesting that TNF promotes remyelination
by acting directly on TNFR2+ oligodendrocyte precursors [135].Ta-
ken together, these observations support the hypothesis that TNF
may not only be a myelinolytic effector molecule of exaggerated
Th1 responses but also have a role in immunoregulation (by induc-
ing apoptosis) and tissue repair (by modulating remyelination).9. GM-CSF
Granulocyte macrophage-colony stimulating factor (GM-CSF)
was originally deﬁned by its ability to promote the proliferation
and differentiation of macrophages, granulocytes, and dendritic
cells from precursors [136,137]. GM-CSF is secreted by cells of
the innate immune system but also by T cells in response to
inﬂammatory stimuli such as IL-1, TNF and LPS [138,139].Notably,
GM-CSF is also a target of IL-23 and is part of the cytokine signa-
ture of Th17 cells. GM-CSF binds to a high-afﬁnity heterodimeric
receptor composed of a GM-CSF speciﬁc a-chain and the common
signal-transduction subunit b (bc), which is shared with the recep-
tors for IL-3 and IL-5 [140,141]. GM-CSF mediates its effects
through different signaling pathways, including the Jak-Stat-
pathway, the MAP kinase pathway and the phosphoinositol-3-
kinase (PI3K) pathway.
GM-CSF has important functions in both physiological and
inﬂammatory conditions. In particular, it is critically involved in
the development of organ-speciﬁc autoimmune diseases including
EAE and collagen-induced arthritis. Mice that are deﬁcient for GM-
CSF or received a neutralizing anti-GM-CSF antibody developed
attenuated EAE [142,143] whereas local administration of GM-
CSF leads to exacerbated EAE [144]. Interestingly, GM-CSF seems
to be a particularly important effector molecule of Th17 cellsbecause anti-GM-CSF antibody treatment selectively suppressed
IL-23-driven forms of EAE while EAE induced by adoptive transfer
of IL-12p70 polarized PLP speciﬁc T cells (Th1 cells) developed irre-
spective of GM-CSF blockade [143]. GM-CSF promotes inﬂamma-
tion in the CNS probably by enhancing the expression of MHC
class II and costimulatory molecules by local and/or inﬁltrating
APCs. Kopf and coworkers demonstrated that GM-CSF facilitates
the secretion of IL-6 and IL-23 by DCs and macrophages and thus
regulates the generation and maintenance of Th17 cells [145]. In
summary, GM-CSF appears to play a profound proinﬂammatory
role in EAE. However, while some evidence points to T cells, there
are still uncertainties on the most relevant cellular sources of GM-
CSF under conditions of chronic inﬂammation in the CNS
[143,146].
10. Individual effector cytokines and T helper cell subsets are
not equivalent
Cytokine knockout mice or mice that transgenically overexpress
a speciﬁc cytokine have been invaluable tools in deciphering the
role of cytokines in chronic inﬂammation and organ speciﬁc auto-
immunity. Unexpected observations like unimpaired susceptibility
to EAE of Ifng/ mice, Tnf/ mice, or Il17f/ mice prompted con-
ceptual debates on whether or not it is possible to deﬁne one sol-
itary cytokine that is responsible for the induction of tissue
inﬂammation in a non-redundant manner. The answer to this
question might rather be no. The ﬁnding that both IFN-c and IL-
17 might be dispensable for induction of EAE, respectively, has
even fueled the swan song by some researchers of Th1 and Th17
cells as pathogenic T cells in EAE and other organ speciﬁc autoim-
mune diseases. However, it must be considered that distinct T
helper cell subsets do not only produce one solitary signature cyto-
kine but a panel of factors whose combined effects might be
responsible for a speciﬁc mode of immunity, i.e. IFN-c is not equiv-
alent to Th1 cells and IL-17 is not equivalent to Th17 cells.
Although there has been a tendency to rush into lineage assign-
ment to particular subsets of T helper cells (perhaps regarding
Th9 and Th22 cells), there is still a large body of experimental evi-
dence to suggest that the concept of distinct T helper cell lineages
is valid. Th1 and Th17 cells are clearly distinct. In the initial reports
on Th17 cells, it was shown that Th17 cells develop in the genetic
absence of Stat1, Stat4, and T-bet that are necessary and sufﬁcient
to induce Th1 cells [147,148]. Moreover, IFN-c and IL-4 are both
inhibitory to the development of Th17 cells. Thus, Th1 cells and
Th17 cells are fundamentally different and induce different types
of immunity in vivo. While Th1 mediated immunity results in
inﬂammatory inﬁltrates dominated by activated macrophages,
Th17 cells induce neutrophilic inﬂammatory responses (Fig. 1).11. Plasticity of T helper cells in EAE
T helper subsets (or even lineages) might be more plastic than
anticipated [149]. Plasticity might be dictated by factors in the
ambient milieu and adapt the T helper cell response to the require-
ments of a speciﬁc niche or compartment. But here too, T cell biol-
ogy is not completely arbitrary but follows speciﬁc rules and is
dependent on speciﬁc nodal points of T cell development. Upon
initial commitment to a speciﬁc developmental program, a T cell
will become responsive to modulatory cytokines in the ambient
milieu based on its receptor equipment. It will be essential
whether WSX1 or IL-6Ra will pair with the constitutively ex-
pressed gp130 to form a functional IL-27 receptor or a functional
IL-6 receptor in this T cell [150,151]. Similarly, expression of IL-
23R that pairs with IL-12Rb1 to form a functional IL-23R or expres-
sion of IL-12Rb2 that also associates with IL-12Rb1 but builds a
Fig. 2. cd T cells restrain regulatory T cell responses. cd T cells sense IL-23 produced
by antigen-presenting cells (APC) via a constitutively expressed IL-23 receptor. In
response to IL-23 cd T cells prevent the TGF-b driven conversion of naïve T cells into
Foxp3 expressing regulatory T cells (Tregs) and antagonize Treg mediated
suppression of ab T cells. This enhances the adaptive immune response by effector
ab T cells.
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plasticity of a T cell that has already been committed to a develop-
mental program [152]. Yet, it depends on the lineage commitment
how fundamental the fate decisions of a given T cell can be. For
example, Th1 cells are relatively stable and cannot easily be repro-
grammed while Th2 cells might be switched into a Th1 phenotype
in a biased experimental system [153]. Adoptively transferred
LCMV speciﬁc Th2 cells can be reprogrammed to express T-bet
and produce IFN-c upon subsequent in vivo infection with LCMV
resulting in protective immunity and memory T cells that co-
express T-bet and Gata3 [153]. Th17 cells appear to be even less
stable. Although it is now clear that in vitro generated Th17 cells
and in vivo generated Th17 cells might be different in terms of
developmental plasticity [154], it remains to be determined
whether memory T cells that express a classic Th17 phenotype
really exist [40]. Using reporter mouse/fate tracking systems, it
has been shown that IL-17A or IL-17F producing T cells are repro-
grammed to produce both IL-17 and IFN-c or IFN-c only in the
spleen and within the CNS [155,156]. Yet, these reprogrammed
‘‘Th17’’ cells (even if they do not produce anything else but IFN-
c) seem to be distinct from classical Th1 cells. Although they lost
expression of IL-17, the expression of IL-23R, IL-1R, and CCR6 that
are not usually expressed by Th1 cells was kept up. Thus, the hom-
ing behavior of reprogrammed Th17 cells and their response to the
innate cytokine milieu in the inﬂamed tissue as well as their mode
of cell death and way of regulation by Tregs might be fundamen-
tally different from Th1 cells.
The contraction of T helper cell populations is an active process
and is regulated differentially depending on the compartment
(lymphoid tissue vs target tissue) and probably also depending
on the effector T cell lineage. While it has long been known that
Th1 cells are very susceptible to Fas/FasL induced cell death
[157]and Th2 cells to GrzB mediated apoptosis [158], it remains
to be determined whether there is a preferred mode of cell death
for Th17 cells. It appears that Th17 cells express high amounts of
IL-10Ra and are more susceptible to IL-10 mediated suppression
than Th1 or Th2 cells. It is likely that IL-10 which might be pro-
vided by Foxp3+ Tregs at the site of inﬂammation, signals directly
into Th17 cells. However, it is not yet clear whether sensing of IL-
10 leads to reprogramming of the inﬂammatory properties of Th17
cells or triggers their physical attrition.
12. Alternative sources of T helper cell associated cytokines
Expression of IL-23R, IL-1R, or CCR6 is highly linked to the
‘‘Th17 phenotype’’ in the inﬂamed tissue. But IL-23R is not only ex-
pressed on Th17 cells. In fact, cells of the innate immune system
like LTi cells, LTi like cells, NK cells, NKT cells, and cd T cells express
large amounts of IL-23R and respond to IL-23 with extensive secre-
tion of IL-17 and IL-22 [159]. We and others could recently show
that IL-23R+ cd T cells enter into the CNS at the time of onset of
clinical signs of EAE and accumulate in the CNS at the peak of
EAE followed by rapid contraction of the cd T cell population
[160,161]. Although CNS derived IL-23R+ cd T cells produce large
amounts of IL-17, cd T cell-derived IL-17 is unlikely to further con-
tribute to IL-17 induced immunopathology because large quanti-
ties of this cytokine are produced by antigen speciﬁc Th17 cells
that are also present in the CNS. However, an effector function un-
ique to cd T cells which is not shared with Th17 cells might be their
capacity to repress Treg responses [161]. IL-23 activated cd T cells
inhibit the generation of Foxp3+ Tregs from conventional T cells in
the peripheral immune compartment and in the target tissue of the
inﬂammation independently of IL-6 or IL-21. In addition, IL-23
activated cd T cells also inhibit the capacity of pre-existent
thymus-derived Tregs to suppress adaptive immune responses by
antigen speciﬁc conventional effector ab T cells (Fig. 2). Thus,IL-23 shapes ab T cell responses in a cell intrinsic manner by guid-
ing and stabilizing their transcriptional program towards patho-
genic effector T cells and in a cell extrinsic manner by tipping
the Treg/effector T cell-balance against Tregs.
Even less is known about the role of IL-23R+ NKT cells. IL-23R+
NKT cells in the spleen rapidly produce large amounts of IL-17
upon stimulation with IL-23 or TcR triggering by aGalCer in an
IL-6 independent manner [162]. However, their contribution to
EAE is unknown while the role of IFN-c or IL-4 producing NKT cells
has been investigated in EAE. Depending on the timing and mode
of their activation with aGalCer, NKT cells can exacerbate EAE
[163] or downmodulate the inﬂammatory response [163–166].
While NKT cells home to secondary lymphoid tissue, gut associated
lymphoid tissue, and liver, recruitment to the CNS is under debate
[162,167,168].
In summary, we propose that the deﬁnition of the temporal pat-
tern of cytokine expression in the inﬂamed tissue can only be the
ﬁrst step to understand the principles of immunopathology in
chronic inﬂammation and autoimmunity. It may be more impor-
tant to deﬁne the cellular sources of effector cytokines and under-
stand their plasticity in response to the environment of a speciﬁc
niche in order to predict immunopathology.
13. Concluding remarks
EAE has been an extremely useful model to study T cell devel-
opment and T cell fate decisions in vivo. Nevertheless, during the
last 2 decades, we have experienced many unexpected results
when analyzing EAE development in cytokine or transcription fac-
tor knock-out animals. Most of the time – after an initial shock –
these experiments promoted our understanding of T cell biology
and brought our concepts of T cell development and effector func-
tions to a higher level of understanding. Thus, where do we stand
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Ifngr/mice, Il17/mice, Il21/mice, Il21r/mice, Il22/mice,
Tnf/ mice, and Tnfr(p75)/ mice are not resistant to EAE
although all of these cytokines are either required for the develop-
ment of Th1 responses or are signature effector cytokines of Th1 or
Th17 cells [31–33,121,133,134,169–171]. On the other hand,
Il23p19/ mice, Il23r/ mice, Il6/ mice, T cell conditional
gp130/ mice, and Gmcsf/ mice are resistant to EAE corroborat-
ing the importance of the IL-23/Th17 axis for the development of
chronic inﬂammation and autoimmunity [36,87,142,172,173].
One conclusion to be drawn from these results is that it might be
unlikely that there is a unique non-redundant effector cytokine
that is the sole pathogenic factor in organ speciﬁc autoimmunity.
Furthermore, T helper cells maintain a certain degree of plasticity
even after commitment to a speciﬁc T helper cell lineage. In addi-
tion, pathogenic effector programs within T helper cells may be
driven by transcription factors like Stat3 or T-bet, and it may be
oversimpliﬁed to exclusively allot the expression of these tran-
scription factors to just one T cell subset. For example Th17 cells
and even Th2 cells are able to express the Th1 transcription factor
T-bet upon sensing particular cytokine cues and only then take on
proinﬂammatory and productive effector functions [153,156].
The development of proinﬂammatory T cell responses has sev-
eral checkpoints. Early during the response – perhaps during T cell
priming in secondary lymphoid tissue and also due to high
amounts of IL-6 receptor expression on naïve conventional T cells
– the availability of IL-6 might dictate whether a pathogenic or a
regulatory adaptive T cell response is primed [38,87]. A late check-
point might be the decision whether a pathogenic response will be
transient or sustained. Here, the responsiveness to IL-23 whose
receptor is not expressed on naïve T cells but on effector T cells
that are committed to the Th17 lineage, will determine the acqui-
sition of sustained effector functions which may no longer be
exclusively associated with the expression of IL-17.In contrast, it
has been shown that committed Th1 cells that keep sensing
IL-12 together with sustained TcR stimulation turn on down-
modulatory programs and start producing IL-10, which has been
shown to be an effector T cell intrinsic mechanism to limit immu-
nopathology [174–178]. This may offer a plausible explanation
why the administration of an anti-p40 antibody (ustekinumab)
that neutralizes both IL-12 and IL-23, had a zero net effect in pa-
tients with RRMS and did not reduce the number of gadolinium
enhancing lesions after 23 weeks [179]. It will be important to
understand the molecular mechanism of these late checkpoints
in order to identify targets for interventional approaches in auto-
immune diseases like MS where the initial steps of T cell commit-
ment have already occurred when the diagnosis is made. We feel
that for these particular questions of T cell development, EAE –
despite all its shortcomings in mimicking the exact clinical course
and histopathology of MS – might be an excellent model.
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